-+ 0.00%
-+ 0.00%
-+ 0.00%

Can-Fite plans Phase IIb trial of namodenoson plus gemcitabine in advanced pancreatic cancer

PUBT·08/17/2026 11:03:29
Listen to the news
Can-Fite plans Phase IIb trial of namodenoson plus gemcitabine in advanced pancreatic cancer
  • Can-Fite outlined new preclinical evidence that namodenoson could strengthen chemotherapy’s anti-cancer effect in pancreatic cancer.
  • The work supports a planned Phase IIb trial using namodenoson with gemcitabine and nab-paclitaxel in advanced pancreatic adenocarcinoma.
  • Findings point to a clearer cell-death response, suggesting the drug may make tumors more vulnerable to standard chemotherapy.
  • Phase IIa clinical results for namodenoson in advanced pancreatic adenocarcinoma will be presented at ESMO Congress 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Can Fite Biofpharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608170700PRIMZONEFULLFEED9811069) on August 17, 2026, and is solely responsible for the information contained therein.